stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) EV/FCF
As of 5 November 2026, Mirum Pharmaceuticals, Inc. (MIRM) trades at a EV/FCF of −21.1×. Over the past ten years it has ranged from −236× (September 2025) to 209× (December 2025); the current reading is higher than 26% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 130× | — |
| FY2024 | −127× | — |
| FY2023 | −13.7× | — |
| FY2022 | −5.3× | — |
| FY2021 | −3.5× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −19.3× | — |
| Jun 2026 | −28.2× | — |
| Mar 2026 | −26.5× | — |
| Dec 2025 | 130× | (30.98%) |
| 18 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | −79.2× |
| ORKA Oruka Therapeutics, Inc. compare | −51.4× |
| KOD Kodiak Sciences Inc. compare | −35.4× |
| CGON CG Oncology, Inc. compare | −26.2× |
| PTCT PTC Therapeutics, Inc. compare | −24.0× |
| MIRM Mirum Pharmaceuticals, Inc. | −21.1× |
| IMVT Immunovant, Inc. compare | −12.2× |
| IONS Ionis Pharmaceuticals, Inc. compare | −10.9× |
| LGND Ligand Pharmaceuticals Incorporated compare | 60.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement